Aminosalicylates

Digestive Diseases

Volumn 30, Issue 1, 2012, Pages 92-99

  Gross, Volker ^a  

^a KLINIKUM ST MARIEN   (Germany)

Author keywords

Aminosalicylates; Diverticulitis; Mesalazine; Segmental colitis associated with diverticulosis; Symptomatic uncomplicated diverticular disease

Indexed keywords

MESALAZINE; PLACEBO; RIFAXIMIN;

ANTIBIOTIC THERAPY; COLITIS; DIVERTICULITIS; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME;

AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; COLITIS; DIVERTICULITIS, COLONIC; HUMANS; MESALAMINE; PROBIOTICS;

EID: 84861051990     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000335906     Document Type: Review

References (45)

1. Parks TG: Natural history of diverticular disease of the colon. Clin Gastroenterol 1975; 4: 53-69.
2. Stollman N, Raskin JB: Diverticular disease of the colon. Lancet 2004; 363: 631-639. (Pubitemid 38264184)
3. Floch CL: Diagnosis and management of acute diverticulitis. J Clin Gastroenterol 2006; 40:S136-S144. (Pubitemid 44174908)
4. Gatta L, Vakil N, Vaira D, Pilotto A, Curlo M, Comparato G, Leandro G, Ferro U, Lera M, Milletti S, Di Mario F: Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol 2010; 44: 113-119.
5. Lenza C, Das KM: Mesalamine in the treatment of diverticular disease. J Clin Gastroenterol 2011; 45:S53-S61.
6. Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D: Enhanced thromboxane A 2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81: 444-449. (Pubitemid 11061542)
7. Sharon P, Ligumsky M, Rachmilewitz D, Zor U: Role of prostaglandins in ulcerative colitis- enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638-640. (Pubitemid 9025499)
8. Keating JJ, Maxwell WJ, Hogan FP, Keeling PWN: Effects of prednisolone, sulphasalazine, 5-aminosalicylic acid and indomethacin on prostaglandin E 2 and leucotrine B 4 production. Jubilee Meeting of the British Society of Gastroenterology, London, 1987, abstr. Th79.
9. Greenfield SM, Boswell DJ, Punchard NA, Thompson RPH: The effects of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid on lipid peroxidation in erythrocytes and prostaglandin production by mononuclear cells. Aliment Pharmacol Ther 1992; 6: 671-683. (Pubitemid 23004315)
10. Lauritsen K, Laursen LS, Bukhave K, Rask- Madsen J: Effect of topical 5-aminosalicylic acid and prednisolone on prostaglandin E 2 and leukotriene B 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91: 837-844. (Pubitemid 16014588)
11. Nielsen OH, Bukhave K, Elmgreen J, Ahnfeldt- Rønne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1987; 32: 577-582. (Pubitemid 17084873)
12. Peskar BM, Dreyling KW, May B, Schaarschmidt K, Goebell H: Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci 1987; 32(suppl):S51-S56.
13. Rachmilewitz D, Eliakim R, Simon P, Ligumsky M, Karmeli F: Role of cytokines and platelet activating factor in the pathogenesis of inflammatory bowel disease; in Goebell H, Malchow H, Ewe K, Koelbel C (eds): Inflammatory Bowel Disease - Progress in Basic Research and Clinical Implications. Dordrecht, Kluwer, 1991, pp 153-159.
14. Mahida YR, Lamming CED, Gallagher A, Hawthorne AB, Hawkey CJ: 5-Aminosalicylic acid is a potent inhibitor of interleukin- 1beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50-54.
15. Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL: Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992; 33: 929-932.
16. Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, Punchard NA, Thompson RPH: Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor - : a novel mechanism of action of sulphasalazine. Gut 1993; 34: 252-256. (Pubitemid 23049122)
17. Molin L, Stendahl O: The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand 1979; 206: 451-457. (Pubitemid 10201934)
18. Rhodes JM, Bartholomew TC, Jewell DP: Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut 1981; 22: 642-647. (Pubitemid 11018267)
19. Wandall JH: Effects of sulphasalazine and its metabolites on neutrophil chemotaxis, superoxide production, degranulation and translocation of cytochrome b-245. Aliment Pharmacol Ther 1991; 5: 609-619.
20. Nikolaus S, Fölsch UR, Schreiber S: Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000; 47: 71-82. (Pubitemid 30085391)
21. Burress GC, Musch MW, Jurivich DA, Welk J, Chang EB: Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology 1997; 113: 1474-1479. (Pubitemid 27461233)
22. Shanahan F, Niederlehner A, Carramanzana N, Anton P: Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 1990; 20: 217-224.
23. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Anwerx J, Metzger D, Wahli W, Desvergne B, Naccari GL, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor- - . J Exp Med 2005; 201: 1205-1215. (Pubitemid 40629065)
24. Allgayer H, Höfer P, Schmidt M, Böhne P, Kruis W, Gugler R: Superoxide hydroxyl and fatty acid radical scavenging by aminosalicylates - direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol 1992; 43: 259-262.
25. Gionchetti P, Guarnieri C, Campieri M, Belluzzi A, Brignola C, Iannone P, Miglioli M, Barbara L: Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 1991; 36: 174-178.
26. Miyachi Y, Yoshioka A, Imamura S, Niwa Y: Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987; 28: 190-195. (Pubitemid 17027390)
27. Hansen O, Stock W: Prophylaktische Operation bei der Divertikelkrankheit des Ko - lons - Stufenkonzept durch exakte Stadieneinteilung. Langenbecks Arch Chir 1999 (suppl II):1257-1260.
28. Broderick-Villa G, Burchette RJ, Collins JC, Abbas MA, Haigh PI: Hospitalization for acute diverticulitis does not mandate routine elective colectomy. Arch Surg 2005; 140: 576-581.
29. Mueller MH, Glatzle J, Kasparek MS, Becker HD, Jehle EC, Zittel TT, Kreis ME: Longterm outcome of conservative treatment in patients with diverticulitis of the sigmoid colon. Eur J Gastroenterol Hepatol 2005; 17: 649-654. (Pubitemid 40733812)
30. Trespi E, Colla C, Panizza P, Polino MG, Venturini A, Bottani G, De Vecchi P, Matti C: Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the colon. Min Gastroenterol Dietol 1999; 45: 245-252. (Pubitemid 30084200)
31. Tursi A, Brandimarte G, Daffina R: Longterm treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Digest Liver Dis 2002; 34: 510-515. (Pubitemid 34830693)
32. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F: Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 2007; 22: 1103-1108. (Pubitemid 47500254)
33. Dr. Falk Pharma GmbH: Mesalazine granules versus placebo for the prevention of recurrence of diverticulitis; in: ClinicalTrials. gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http:// clinicaltrials.gov/ct2/show/NCT00695643.
34. Dr. Falk Pharma GmbH: Two doses mesalazine granules versus placebo for the prevention of recurrence of diverticulitis; in: ClinicalTrials. gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http://clinicaltrials.gov/ct2/show/ NCT01038739.
35. Shire Pharmaceutical Development, Whitaker T: Prevention of recurrence of diverticulitis (PREVENT 1); in: ClinicalTrials.gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http:// clinicaltrials.gov/ct2/show/NCT00545740.
36. Shire Pharmaceutical Development, Whitaker T: Prevention of recurrence of diverticulitis (PREVENT 2); in: ClinicalTrials.gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http:// clinicaltrials.gov/ct2/show/NCT00545103.
37. Comparato G, Fanigliulo L, Cavallaro LG, Aragona G, Cavestro GM, Iori V, Maino M, Mazzocchi G, Muzzetto P, Colla G, Sianesi M, FranzéA, Di Mario F: Prevention of complications and symptomatic recurrence in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 2007; 52: 2934-2941. (Pubitemid 47512549)
38. Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci 2007; 52: 671-674.
39. Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon. A prospective, randomized, open-label study. J Clin Gastroenterol 2006; 40: 312-316. (Pubitemid 44309523)
40. Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology 2008; 55: 916-920. (Pubitemid 351975955)
41. Kruis W, Meier E, Schumacher M, Mickisch O, Schneider W, Greinwald R, Müller R: Treatment of painful diverticular disease of the colon with mesalamine: a placebo-controlled study. Gastroenterology 2007; 132: A- 191.
42. Stollman N, Magowan S, Shanahan F, Quigley E: Efficacy of delayed-release mesalamine in the prevention of GI symptoms following acute diverticulitis: results of the DIVA trial. Am J Gastroenterology 2010; 105(suppl 1):S139.
43. University of Nottingham, Cartledge P: Mechanistic randomized controlled trial (RCT) of mesalazine in symptomatic diverticular disease; in: ClinicalTrials.gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http://clinicaltrials. gov/ct2/show/NCT00663247.
44. Imperiali G, Meucci G, Alvisi C, Fasoli R, Ferrara A, Girelli CM, Rocca F, Saibeni S, Minoli G, Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Segmental colitis associated with diverticula: a prospective study. Am J Gastroenterol 2000; 95: 1014-1016. (Pubitemid 30196739)
45. Mulhall AM, Mahid SS, Petras RE, Galandiuk S: Diverticular disease associated with inflammatory bowel disease-like colitis: a systematic review. Dis Colon Rectum 2009; 52: 1072-1079.